CT-guided, automated detection of lung tumors on PET images

Progress in Biomedical Optics and Imaging - Proceedings of SPIE

Volumn 6915, Issue , 2008, Pages

  Cui, Yunfeng ^a   Zhao, Binsheng ^a   Akhurst, Timothy J ^a   Yan, Jiayong ^a   Schwartz, Lawrence H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Computer aided detection; CT; Lung tumor; PET; Response assessment

Indexed keywords

COMPUTER AIDED DIAGNOSIS; MUSCLE; TUMORS;

LUNG TUMORS; RESPONSE ASSESSMENT;

COMPUTERIZED TOMOGRAPHY;

EID: 44349099091     PISSN: 16057422     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.770549     Document Type: Conference Paper

References (16)

1. Mac Manus, M. P., Hicks, R. J., Matthews, J. P., McKenzie, A., Rischin, D., Salminen, E. K. and Ball, D. L., "Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer," J. Clin. Oncol. 21(7), 1285-1292 (2003).
2. Weber, W. A., Petersen, V., Schmidt, B., Tyndale-Hines, L., Link, T., Peschel, C and Schwaiger, M., "Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use," J. Clin. Oncol. 21(14), 2651-2657 (2003).
3. Shankar, L. K. and Sullivan, D. C., "Functional imaging in lung cancer," J. Clin. Oncol. 23(14), 3203-3211 (2005).
4. Chesnay, E., Babin, E., Constans, J. M., Agostini, D., Bequignon, A., Regeasse, A., Sobrio, F. and Moreau, S., "Early response to chemotherapy in hypopharyngeal cancer: Assessment with C-11-methionine PET, correlation with morphologic response, and clinical outcome," J. Nucl. Med. 44(4), 526-532 (2003).
5. 18F]Fluorodeoxyglucose," J Clin Oncol 24(28), 4587-4593 (2006).
6. 18F]-2-fluoro-2-deoxy-i/-glucose and positron emission tomography: an overview of different analytical methods," Eur. J. Nucl. Med. Mol. Imaging 27(6), 731-743 (2000).
7. Shankar, L. K., Hoffman, J. M., Bacharach, S., Graham, M. M., Karp, J., Lammertsma, A. A., Larson, S., Mankoff, D. A., Siegel, B. A., den Abbeele, A., Yap, J. and Sullivan, D., "Consensus recommendations for the use of F-18-FDG PET as an indicator of therapeutic response in patients in national cancer institute trials," J. Nucl. Med. 47(6), 1059-1066 (2006).
8. Larson, S. M., Erdi, Y., Akhurst, T., Mazumdar, M., Macapinlac, H. A., Finn, R. D., Casilla, C., Fazzari, M., Srivastava, N., Yeung, H. W. D., Humm, J. L., Guillem, J., Downey, R., Karpeh, M., Cohen, A. E. and Ginsberg, R., "Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging: The Visual Response Score and the Change in Total Lesion Glycolysis," Clinical Positron Imaging 2(3), 159-171 (1999).
9. Potesil, V., Huang, X. and Zhou, X. S., "Automated tumor delineation using joint PET/CT information," Medical Imaging 2007: Computer-Aided Diagnosis. Proc. SPIE 6514, 65142Y (2007).
10. Weber, W. A., "PET for response assessment in oncology: radiotherapy and chemotherapy," Br. J. Radiol. 78, 42-49 (2005).
11. Larson, S. M. and Schwartz, L. H., "F-18-FDG PET as a candidate for "Qualified Biomarker": Functional assessment of treatment response in oncology," J. Nucl. Med. 47(6), 901-903 (2006).
12. 18F-FDG PET Scans," J Nucl Med 48(9), 1449-1458 (2007).
13. Gunilla, B., "Distance transformations in digital images," Computer Vision, Graphics, and Image Processing 34(3), 344-371 (1986).
14. Li, Q., Sone, S. and Doi, K., "Selective enhancement filters for nodules, vessels, and airway walls in two- and three-dimensional CT scans," Med. Phys. 30(8), 2040-2051 (2003).
15. Sato, Y., Westin, C. F., Bhalerao, A., Nakajima, S., Shiraga, N., Tamura, S. and Kikinis, R., "Tissue classification based on 3D local intensity structures for volume rendering," IEEE Trans. Vis. Comput. Graph. 6(2), 160-180 (2000).
16. Riely, G. J., Kris, M. G., Zhao, B., Akhurst, T., Milton, D. T., Moore, E., Tyson, L., Pao, W., Rizvi, N. A., Schwartz, L. H. and Miller, V. A., "Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus," Clin. Cancer Res. 13(17), 5150-5155 (2007).